002873 Stock Overview
Engages in the research and development, production, and sale of new Chinese patent medicines in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Guiyang Xintian Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥9.21 |
| 52 Week High | CN¥14.33 |
| 52 Week Low | CN¥7.49 |
| Beta | -0.17 |
| 1 Month Change | -6.50% |
| 3 Month Change | -19.91% |
| 1 Year Change | -13.76% |
| 3 Year Change | -30.38% |
| 5 Year Change | 4.28% |
| Change since IPO | 15.76% |
Recent News & Updates
Why Guiyang Xintian PharmaceuticalLtd's (SZSE:002873) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 04
Earnings Tell The Story For Guiyang Xintian Pharmaceutical Co.,Ltd. (SZSE:002873) As Its Stock Soars 25%
Oct 01Recent updates
Why Guiyang Xintian PharmaceuticalLtd's (SZSE:002873) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 04Earnings Tell The Story For Guiyang Xintian Pharmaceutical Co.,Ltd. (SZSE:002873) As Its Stock Soars 25%
Oct 01Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
Jun 05Weak Statutory Earnings May Not Tell The Whole Story For Guiyang Xintian PharmaceuticalLtd (SZSE:002873)
Apr 19Investors Still Aren't Entirely Convinced By Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) Earnings Despite 28% Price Jump
Mar 11Shareholder Returns
| 002873 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.3% | 0.4% | 0.6% |
| 1Y | -13.8% | 0.2% | 12.8% |
Return vs Industry: 002873 underperformed the CN Pharmaceuticals industry which returned 0.2% over the past year.
Return vs Market: 002873 underperformed the CN Market which returned 12.8% over the past year.
Price Volatility
| 002873 volatility | |
|---|---|
| 002873 Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in CN Market | 10.9% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 002873 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002873's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 1,958 | Da Lun Dong | www.gyxtyy.com |
Guiyang Xintian Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of new Chinese patent medicines in China. The company offers products in various dosage forms, including hard capsules, mixtures, granules, gels, tablets, syrups, wines, dews, etc. Its products are used for the treatment of anti-tumor, gynecological, urological system diseases, oral, breast and thyroid, anti-cold, heat clearing, blood tonic, and cardiovascular diseases.
Guiyang Xintian Pharmaceutical Co.,Ltd. Fundamentals Summary
| 002873 fundamental statistics | |
|---|---|
| Market cap | CN¥1.96b |
| Earnings (TTM) | CN¥54.16m |
| Revenue (TTM) | CN¥839.16m |
36.2x
P/E Ratio2.3x
P/S RatioIs 002873 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002873 income statement (TTM) | |
|---|---|
| Revenue | CN¥839.16m |
| Cost of Revenue | CN¥214.49m |
| Gross Profit | CN¥624.67m |
| Other Expenses | CN¥570.51m |
| Earnings | CN¥54.16m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 25, 2025
| Earnings per share (EPS) | 0.25 |
| Gross Margin | 74.44% |
| Net Profit Margin | 6.45% |
| Debt/Equity Ratio | 71.0% |
How did 002873 perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield30%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 20:44 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guiyang Xintian Pharmaceutical Co.,Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mengmeng Han | Ping An Securities Co. Ltd. |
| Song Yang | Tianfeng Securities Brokerage Co., Ltd |